secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001867096-22-000017
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris reaffirms 2021 net sales guidance at high-end $76-80M, 55% YoY growth
---------------------------------------------------------------------------

- Preliminary 2021 pro forma net sales expected at high-end of $76-80M guidance, ~55% growth vs 2020.
- Year-end 2021 preliminary cash, equivalents, and investments ~$102M.
- Over 20M Medicaid lives in IL, TN, PA, OH, CA now have unrestricted access to Gvoke as of Jan 1, 2022.
- Third product Recorlev approved; launch in near term; additional $30M raised early 2022.
- Full Q4 and FY 2021 results and 2022 guidance expected in March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/0001867096-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/xers-20220118.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer